Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Chief Medical Officer | December 15, 2024 | December 18, 2024 |
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Chief Medical Officer | August 07, 2020 | August 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date December 15, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,518 |
Reported balance
After 2024-12-15 transaction · row 1
1 source rowRow 1 · 2024-12-15 · Tax withholding · Disposed 7,856 · Balance 87,518 F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
CHINOOK THERAPEUTICS, INC.
Report date August 07, 2020 · Filed August 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,462 |
Reported balance
After 2020-08-07 transaction · row 1
1 source rowRow 1 · 2020-08-07 · Sale · Disposed 3,538 · Balance 8,462 F1: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.48 to $2.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.48 to $2.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2024 Filed Dec 18, 2024 01:36 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 7,856 | $16.08 | $126,324.48 |
DisclosureSEC source: 0001724521-24-000181 · wk-form4_1734485783.xml · nonDerivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,518 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 22:42 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Tax withholdingCommon Stock | 5,385 | $17.95 | $96,660.75 |
DisclosureSEC source: 0001724521-24-000149 · wk-form4_1726612922.xml · nonDerivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,933 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. F2 · balance_after: Includes 1,123 shares purchased on 5/31/2024 through the Company's Employee Stock Purchase Plan. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:38 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (right to buy) · Derivative | 113,700 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001724521-24-000024 · wk-form4_1706229520.xml · derivative · entry 2 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,700 Underlying: Common Stock · 113,700 shares Expires 2034-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:38 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001724521-24-000024 · wk-form4_1706229520.xml · nonDerivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,195 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 1,540 | $18.09 | $27,858.60 |
DisclosureSEC source: 0001724521-23-000069 · wk-form4_1703106628.xml · nonDerivative · entry 2 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,195 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 21:10 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 1,507 | $17.74 | $26,734.18 |
DisclosureSEC source: 0001724521-23-000069 · wk-form4_1703106628.xml · nonDerivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,735 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.45 to $17.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 651 shares purchased on 11/30/2023 through the Company's Employee Stock Purchase Plan. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:47 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | Disposition to issuerCommon Stock | 3,708 | $20.40 | $75,643.20 |
DisclosureSEC source: 0001724521-23-000008 · wk-form4_1695242857.xml · nonDerivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,591 F1 · shares: Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. F2 · balance_after: Includes 799 shares purchased on 5/31/2023 through the Company's Employee Stock Purchase Plan. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:55 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 138,200 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001209191-23-004876 · doc4.xml · derivative · entry 2 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,200 Underlying: Common Stock · 138,200 shares Expires 2033-01-22 F2 · derivative.exercise_date: The option becomes exercisable in 48 equal monthly installments after January 1, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 22:55 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004876 · doc4.xml · nonDerivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,500 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 20:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047316 · doc4.xml · derivative · entry 2 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2032-08-22 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after August 1, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 20:08 UTC | Arcus Biosciences, Inc. RCUS · Entity 4104 | GrantCommon Stock | 42,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047316 · doc4.xml · nonDerivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments beginning September 15, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 16:06 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 3,538 | $2.55 | $9,036.41 |
DisclosureSEC source: 0001567619-20-014729 · doc1.xml · nonDerivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,462 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.48 to $2.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 17:26 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011635 · doc1.xml · nonDerivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · shares: Represents Restricted Stock Units ("RSUs") that are fully vested. F2 · balance_after: Includes 10,000 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F3 · balance_after: Reflects the adjusted total which includes the purchase of 2,000 shares under the Employee Stock Purchase Plan on May 15, 2020. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 18:28 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001567619-20-004745 · doc1.xml · derivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-02-20 F1 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of February 21, 2020. Read SEC document |
| May 13, 2019 Filed May 15, 2019 19:02 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantInitial Option Grant · Derivative | 400,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001567619-19-011351 · doc1.xml · derivative · entry 1 Nuyten Dimitry SA · CIK 0001776564 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-05-12 F1 · derivative.exercise_date: The shares subject to the initial option grant vest 1/4 after the first year, the remaining shares will vest monthly over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.